SURGEPAYS INC (SURG)

US86882L2043 - Common Stock

3.73  -0.13 (-3.37%)

Premarket: 3.75 +0.02 (+0.54%)

Fundamental Rating

6

Taking everything into account, SURG scores 6 out of 10 in our fundamental rating. SURG was compared to 22 industry peers in the Wireless Telecommunication Services industry. SURG is in great health and has no worries on liquidiy or solvency at all, but the profibility rating is only average. SURG may be a bit undervalued, certainly considering the very reasonable score on growth



4

1. Profitability

1.1 Basic Checks

In the past year SURG was profitable.
In the past year SURG had a positive cash flow from operations.
SURG had negative earnings in 4 of the past 5 years.
The reported operating cash flow has been mixed in the past 5 years: SURG reported negative operating cash flow in multiple years.

1.2 Ratios

With an excellent Return On Assets value of 49.20%, SURG belongs to the best of the industry, outperforming 100.00% of the companies in the same industry.
The Return On Equity of SURG (73.01%) is better than 95.24% of its industry peers.
SURG has a Return On Invested Capital of 44.09%. This is amongst the best in the industry. SURG outperforms 100.00% of its industry peers.
Industry RankSector Rank
ROA 49.2%
ROE 73.01%
ROIC 44.09%
ROA(3y)-7.37%
ROA(5y)-50.43%
ROE(3y)-107.11%
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A

1.3 Margins

SURG has a better Profit Margin (15.04%) than 85.71% of its industry peers.
SURG has a Operating Margin (13.76%) which is in line with its industry peers.
SURG's Gross Margin of 25.99% is on the low side compared to the rest of the industry. SURG is outperformed by 90.48% of its industry peers.
In the last couple of years the Gross Margin of SURG has declined.
Industry RankSector Rank
OM 13.76%
PM (TTM) 15.04%
GM 25.99%
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y78.16%
GM growth 5Y-10.03%

9

2. Health

2.1 Basic Checks

With a Return on Invested Capital (ROIC) well above the Cost of Capital (WACC), SURG is creating value.
SURG has more shares outstanding than it did 1 year ago.
The number of shares outstanding for SURG has been increased compared to 5 years ago.
Compared to 1 year ago, SURG has an improved debt to assets ratio.

2.2 Solvency

SURG has an Altman-Z score of 8.00. This indicates that SURG is financially healthy and has little risk of bankruptcy at the moment.
SURG has a better Altman-Z score (8.00) than 95.24% of its industry peers.
The Debt to FCF ratio of SURG is 0.49, which is an excellent value as it means it would take SURG, only 0.49 years of fcf income to pay off all of its debts.
SURG has a better Debt to FCF ratio (0.49) than 90.48% of its industry peers.
SURG has a Debt/Equity ratio of 0.18. This is a healthy value indicating a solid balance between debt and equity.
With an excellent Debt to Equity ratio value of 0.18, SURG belongs to the best of the industry, outperforming 85.71% of the companies in the same industry.
Industry RankSector Rank
Debt/Equity 0.18
Debt/FCF 0.49
Altman-Z 8
ROIC/WACC5.26
WACC8.38%

2.3 Liquidity

A Current Ratio of 2.63 indicates that SURG has no problem at all paying its short term obligations.
Looking at the Current ratio, with a value of 2.63, SURG belongs to the top of the industry, outperforming 90.48% of the companies in the same industry.
A Quick Ratio of 1.91 indicates that SURG should not have too much problems paying its short term obligations.
The Quick ratio of SURG (1.91) is better than 90.48% of its industry peers.
Industry RankSector Rank
Current Ratio 2.63
Quick Ratio 1.91

4

3. Growth

3.1 Past

SURG shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 3600.00%, which is quite impressive.
SURG shows quite a strong growth in Revenue. In the last year, the Revenue has grown by 12.83%.
SURG shows a strong growth in Revenue. Measured over the last years, the Revenue has been growing by 55.26% yearly.
EPS 1Y (TTM)3600%
EPS 3YN/A
EPS 5YN/A
EPS growth Q2Q-20%
Revenue 1Y (TTM)12.83%
Revenue growth 3Y36.1%
Revenue growth 5Y55.26%
Revenue growth Q2Q-10.8%

3.2 Future

No EPS estimates are available, so we could not analyze the future EPS growth and evolution.
No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
EPS Next Y27.74%
EPS Next 2YN/A
EPS Next 3YN/A
EPS Next 5YN/A
Revenue Next Year5.41%
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A

3.3 Evolution

No EPS estimates are available, so we could not analyze the future EPS growth and evolution.
No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.

8

4. Valuation

4.1 Price/Earnings Ratio

The Price/Earnings ratio is 2.66, which indicates a rather cheap valuation of SURG.
SURG's Price/Earnings ratio is rather cheap when compared to the industry. SURG is cheaper than 100.00% of the companies in the same industry.
Compared to an average S&P500 Price/Earnings ratio of 26.42, SURG is valued rather cheaply.
With a Price/Forward Earnings ratio of 2.09, the valuation of SURG can be described as very cheap.
Compared to the rest of the industry, the Price/Forward Earnings ratio of SURG indicates a rather cheap valuation: SURG is cheaper than 95.24% of the companies listed in the same industry.
SURG is valuated cheaply when we compare the Price/Forward Earnings ratio to 22.74, which is the current average of the S&P500 Index.
Industry RankSector Rank
PE 2.66
Fwd PE 2.09

4.2 Price Multiples

SURG's Enterprise Value to EBITDA ratio is rather cheap when compared to the industry. SURG is cheaper than 95.24% of the companies in the same industry.
Based on the Price/Free Cash Flow ratio, SURG is valued a bit cheaper than the industry average as 76.19% of the companies are valued more expensively.
Industry RankSector Rank
P/FCF 6.99
EV/EBITDA 2.9

4.3 Compensation for Growth

The low PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates a rather cheap valuation of the company.
PEG (NY)0.1
PEG (5Y)N/A
EPS Next 2YN/A
EPS Next 3YN/A

0

5. Dividend

5.1 Amount

SURG does not give a dividend.
Industry RankSector Rank
Dividend Yield N/A

SURGEPAYS INC

NASDAQ:SURG (3/27/2024, 8:00:01 PM)

Premarket: 3.75 +0.02 (+0.54%)

3.73

-0.13 (-3.37%)

Chartmill FA Rating
GICS SectorCommunication Services
GICS IndustryGroupTelecommunication Services
GICS IndustryWireless Telecommunication Services
Earnings (Last)
Earnings (Next)
Inst Owners
Inst Owner Change
Ins Owners
Ins Owner Change
Market Cap71.95M
Analysts
Price Target
Dividend
Industry RankSector Rank
Dividend Yield N/A
Dividend Growth(5Y)
DP
Div Incr Years
Div Non Decr Years
Ex-Date
Surprises & Revisions
EPS beat(2)
Avg EPS beat(2)
Min EPS beat(2)
Max EPS beat(2)
EPS beat(4)
Avg EPS beat(4)
Min EPS beat(4)
Max EPS beat(4)
EPS beat(8)
Avg EPS beat(8)
EPS beat(12)
Avg EPS beat(12)
EPS beat(16)
Avg EPS beat(16)
Revenue beat(2)
Avg Revenue beat(2)
Min Revenue beat(2)
Max Revenue beat(2)
Revenue beat(4)
Avg Revenue beat(4)
Min Revenue beat(4)
Max Revenue beat(4)
Revenue beat(8)
Avg Revenue beat(8)
Revenue beat(12)
Avg Revenue beat(12)
Revenue beat(16)
Avg Revenue beat(16)
PT rev (1m)
PT rev (3m)
EPS NQ rev (1m)
EPS NQ rev (3m)
EPS NY rev (1m)
EPS NY rev (3m)
Revenue NQ rev (1m)
Revenue NQ rev (3m)
Revenue NY rev (1m)
Revenue NY rev (3m)
Valuation
Industry RankSector Rank
PE 2.66
Fwd PE 2.09
P/S
P/FCF
P/OCF
P/B
P/tB
EV/EBITDA
EPS(TTM)
EY
EPS(NY)
Fwd EY
FCF(TTM)
FCFY
OCF(TTM)
OCFY
SpS
BVpS
TBVpS
PEG (NY)0.1
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA 49.2%
ROE 73.01%
ROCE
ROIC
ROICexc
ROICexgc
OM 13.76%
PM (TTM) 15.04%
GM 25.99%
FCFM
ROA(3y)
ROA(5y)
ROE(3y)
ROE(5y)
ROIC(3y)
ROIC(5y)
ROICexc(3y)
ROICexc(5y)
ROICexgc(3y)
ROICexgc(5y)
ROCE(3y)
ROCE(5y)
ROICexcg growth 3Y
ROICexcg growth 5Y
ROICexc growth 3Y
ROICexc growth 5Y
OM growth 3Y
OM growth 5Y
PM growth 3Y
PM growth 5Y
GM growth 3Y
GM growth 5Y
F-Score
Asset Turnover3.27
Health
Industry RankSector Rank
Debt/Equity 0.18
Debt/FCF
Debt/EBITDA
Cap/Depr
Cap/Sales
Interest Coverage
Cash Conversion
Profit Quality
Current Ratio 2.63
Quick Ratio 1.91
Altman-Z
F-Score
WACC
ROIC/WACC
Cap/Depr(3y)
Cap/Depr(5y)
Cap/Sales(3y)
Cap/Sales(5y)
Profit Quality(3y)
Profit Quality(5y)
Growth
EPS 1Y (TTM)3600%
EPS 3YN/A
EPS 5Y
EPS growth Q2Q
EPS Next Y27.74%
EPS Next 2Y
EPS Next 3Y
EPS Next 5Y
Revenue 1Y (TTM)12.83%
Revenue growth 3Y36.1%
Revenue growth 5Y
Revenue growth Q2Q
Revenue Next Year
Revenue Next 2Y
Revenue Next 3Y
Revenue Next 5Y
EBIT growth 1Y
EBIT growth 3Y
EBIT growth 5Y
EBIT Next Year
EBIT Next 3Y
EBIT Next 5Y
FCF growth 1Y
FCF growth 3Y
FCF growth 5Y
OCF growth 1Y
OCF growth 3Y
OCF growth 5Y